ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2233

Porphyromonas Gingivalis peptidylarginine Deiminase Exacerbates Collagen-Induced Arthritis In C57BL/6 mice 

Saba Alzabin1,2, Anne-Marie Quirke2, Elena B. Lugli2, Muslima Choudhury2,3, Peter J. Charles4, Richard O. Williams5 and Patrick Venables6, 1Epistem Ltd., Manchester, United Kingdom, 2University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom, 3Kennedy Institute of Rheumatology, London, United Kingdom, 4Oxford University, Kennedy Institute of Rheumatology, Oxford, United Kingdom, 5Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, 6Kennedy Institute of Rheumatology, Oxford, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, citrullination and rheumatoid arthritis, PAD, Periodontitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is increasing molecular and epidemiological evidence linking Porphyromonas gingivalis to RA. P. gingivalis is unique amongst periodontal pathogens in possessing a citrullinating enzyme peptidylarginine deiminase (PPAD) with the potential to generate citrullinated antigens driving the autoimmune response in RA. To examine the effect of PPAD on collagen induced arthrititis (CIA), we co-immunised C57BL/6 mice with PPAD and collagen and measured disease outcome by clinical scores, histology and antibody responses. 

Methods: Male C57BL/6 animals (8-10 weeks, n=15/group) were immunised with 200ug type II collagen (cII) in CFA alone, or cII emulsified in 50ug PPAD or emulsified in 50ug of an enzymatically inactive PPAD mutant control (C531A) in CFA at the base of the tail.  Mice were monitored daily for the first appearance of peripheral joint oedema.  Clinical scores and paw swelling measurements were recorded daily and mice were culled after 10 days of disease onset.  Their joints were fixed in 10% buffered formalin and decalcified with 10%EDTA for histological analysis, and serum was collected by terminal cardiac puncture for antibody titres. Antibodies to collagen, CCP2 and recombinant PPAD were measured by ELISA.

Results: Between days 5-10 post disease onset, PPAD immunised mice had a significantly increased clinical score of arthritis (mean = 6.83, p=0.0126) compared to cII alone immunised mice (mean= 3.40).  There was a minor increase in the clinical scores when C351A immunised mice (mean=4.77) were compared to mice immunised with cII alone, but this did not reach statistical significance (p=0.290). This correlated with an increase in PPAD-specific antibodies (p< 0.0001) in PPAD immunised mice when compared to the mutant C531A or cII immunised mice.  There was no increase in anti-collagen antibodies in the PPAD immunised mice and anti-CCP2 antibodies where negative in all 3 groups. Histological analysis showed that PPAD immunisation resulted in increased synovitis and joint erosion (p=0.021) when compared to cII controls.    

Conclusion: PPAD immunisation exacerbated both clinical and histological parameters of CIA.  There was no significant difference between the mice immunised with cII alone and the mice co-immunised with the enzymatically inactive mutant (C351A), supporting the hypothesis that enzymatic activity of PPAD is necessary to drive its arthritogenic effect. These data indicate a molecular mechanism that explains the link between periodontitis and RA and suggests potential therapeutic benefit by targeting PPAD.


Disclosure:

S. Alzabin,
None;

A. M. Quirke,
None;

E. B. Lugli,
None;

M. Choudhury,
None;

P. J. Charles,
None;

R. O. Williams,
None;

P. Venables,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/porphyromonas-gingivalis-peptidylarginine-deiminase-exacerbates-collagen-induced-arthritis-in-c57bl6-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology